PRIME is a research study for HIV-negative men who have sex with men, inject drugs and use methamphetamine. PRIME is investigating ways to help people take daily, oral pre-exposure prophylaxis or PrEP (Descovy), to reduce their HIV risk. The study is conducted by the Center on Substance Use and Health of the San Francisco Department of Public Health.
Descovy is an HIV prevention medication that reduces your risk of contracting HIV. PrEP is approved by the Food and Drug Administration for the prevention of HIV among people exposed to HIV through sex or injecting drugs.
To see if you may be eligible to participate, call us at 628-217-6319 or send us your contact information using the contact form on this page to see if you might qualify. If you do, we will set up the first screening visit for you to come in to our office to see if you meet further study criteria. Determining study eligibility involves meeting with a research associate, clinical staff and various other procedures, which will be explained to you during the informed consent process.
If you are eligible and choose to participate, you will receive daily, oral Descovy for PrEP and counseling to help you take your PrEP consistently. Some participants will also be randomly assigned to use a video app to record taking their daily PrEP dose. Participants randomized to the video arm, will receive a small payment for completing and uploading these videos.
Participants will be in the study for 24 weeks (6 months) and visit our office approximately seven times over the duration of the study.
Eligible participants can earn up to $612 for completing all study activities and all procedures.
Since the study is investigating approaches to support the use of an HIV prevention drug, this study is open to HIV-negative participants only. However, the Center on Substance Use and Health does conduct other research that is open for individuals regardless of their HIV status. For more information on our Center, please visit www.csuhsf.org